Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus TP chemotherapy in resectable locally advanced oral squamous cell carcinoma
NCT05798793Phase 3Recruiting
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in oral squamous cell carcinoma (OSCC). Started Nov 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT05798793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798793.